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Because of its large surface area and easy access for both delivery and monitoring, the skin is an attractive
target for gene therapy for cutaneous diseases, vaccinations and several metabolic disorders. The critical
factors for DNA delivery to the skin by electroporation (EP) are effective expression levels and minimal or no
tissue damage. Here, we evaluated the non-invasive multielectrode array (MEA) for gene electrotransfer. For
these studies we utilized a guinea pig model, which has been shown to have a similar thickness and structure
to human skin. Our results demonstrate significantly increased gene expression 2 to 3 logs above injection of
plasmid DNA alone over 15 days. Furthermore, gene expression could be enhanced by increasing the size of
the treatment area. Transgene-expressing cells were observed exclusively in the epidermal layer of the skin.
In contrast to caliper or plate electrodes, skin EP with the MEA greatly reduced muscle twitching and resulted
in minimal and completely recoverable skin damage. These results suggest that EP with MEA can be an
efficient and non-invasive skin delivery method with less adverse side effects than other EP delivery systems
and promising clinical applications.
© 2011 Elsevier B.V. All rights reserved.
1. Introduction
In the past two decades electroporation (EP) has received
increased attention for its advantages compared to viral vectors for
use in gene delivery. EP has been demonstrated to be an efficient non-
viral in vivo gene delivery method by several independent research
groups [1–5]. Diverse electrodes such as calipers, tweezers, needle
arrays and microneedle arrays have been designed and tested in
different species [6–10]. Various electrical parameters have been
studied for their expression efficiency and adverse effects [6,11]. In
vivo gene delivery by EP has been reported to achieve effective gene
expression in various tissues and organs [12], such as liver [1], skin
[13], muscle [14], brain [15], eye [16], lung [17], spleen [18], kidney
[19], bladder [20], testis [21], artery [22], and tumors [2].
The skin contains large numbers of potent antigen-presenting
cells, Langerhans cells and dermal dendritic cells, as well as an
abundant blood supply in the dermal layer of the skin [23], whichmay
help transgenic products distribute into distant organs through
circulation [24]. These advantages make delivery of therapeutic
genes to the skin very attractive, particularly, for i) the treatment of
local diseases including skin cancer, chronic ulcer, burn, psoriasis;
ii) vaccination against infectious diseases such as HIV, anthrax,
malaria, as well as non-infectious diseases like cancer; iii) the
correction of systemic or metabolic disorders like anemia in chronic
kidney disease. Previous studies have shown that EP efficiently
delivers plasmid DNA to the skin resulting in a 10–1000 fold increase
of local and serum expression [24–27]. Skin EP delivery was
successfully performed in rodent, porcine and non-human primate
model systems [13,24,25]. Intradermal delivery of plasmid VEGF
(165), FGF-2 or TGF-β by EP has been observed to promote wound
healing in rat or mouse models [28–30]. Significant serum levels were
achieved by EP delivery of both EPO and IL-12 plasmid DNA to the skin
[24,31–33]. A number of studies demonstrated that significant tumor
regression could be achieved by electrically mediated delivery of
plasmids expressing IFN-α, IL-12, IL-2, IL-15, IL-18, GM-CSF and other
transgenes to cutaneous tumors (melanoma, squamous cell carcino-
ma) [6]. In our mouse melanomamodel [32,34], intratumoral EP of IL-
12 plasmid resulted in complete tumor regression rates of 80%. Those
mice were also resistant to subsequent tumor challenge. Moreover,
our phase I human trial of IL-12 EP treatment of metastatic melanoma
showed that distant untreated lesions could also regress, suggesting
that not only had a local response been mounted against treated
tumors but also a systemicmemory response had been generated [35].
Current skin EP systems, utilize, for example, invasive needle
electrodes as well as plate electrodes (calipers, forceps, etc.) and
typically induce significant muscle twitching and discomfort and
treatment can result in skin damage [25]. To overcome the pitfalls of
these electrode designs, we developed a new non-invasive electrode
known as multielectrode array (MEA). In previous studies [27], we
reported that skin EP with the MEA could achieve comparable (in rat)
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or higher expression (in guinea pig) as compared to plate electrodes,
while the applied voltage and muscle stimulation was greatly
reduced. In the current study, we further modified the MEA to
include flexible spring electrodes in the substrate to assure a full
contact between all of the electrodes and the skin. We then
characterized several critical aspects relevant to therapeutic applica-
tions. DNA delivery was tested in a guinea pig model, which has
similar skin thickness and structure to human skin [36,37]. Localized
transgene expression and kinetics were assessed by the measurement
of luciferase activity with an in vivo bioluminescence scan. The
evaluation of the MEA has also included the correlation between
expression and the size of the treated area, potential tissue damage,
DNA distribution and localization of gene-expressing cells.
2. Materials and methods
2.1. Animals
Female Hartley guinea pigs used in this study were 4 to 6 weeks
old from Elm Hill Labs (Chelmsford, MA, USA). All experimental
procedures were approved by the Institutional Animal Care and Use
Committee of the Old Dominion University.
2.2. Plasmids
The reporter plasmids encoded luciferase (gWiz-Luc) and green
fluorescent protein (gWiz-GFP) were both from Aldevron (Fargo, ND,
USA). Fluorescein-labeled plasmid MIR 7907 and CyTM3-labeled
plasmid MIR7905 (Mirus Bio LLC, Madison, WI, USA) were used to
observe DNA distribution.
2.3. DNA injection and in vivo electroporation
Prior to delivery, animals were anesthetized in an induction
chamber charged with 3% isoflurane in O2 then fitted with a standard
rodent mask and kept under general anesthesia during the procedure.
Guinea pigs received intradermal (i.d.) injections of 50 μL or 200 μL
plasmid DNA (2 μg/μL dissolved in saline) on the left and right flanks.
Immediately after DNA administration, a MEA electrode with 4×4 2-
mm-apart pins was placed over the injection site(s). Voltage was
applied (each pair of electrodes was programmed to administer four
pulses with total 72 pulses [27], electric field was 250 V/cm, pulse
duration 150 ms and 150 ms delay). Electroporation was performed
using the UltraVolt Model: Rack-2-500-00230 (UltraVolt, Inc. Ron-
konkomo, NY, USA). The electroporation parameters we chose here
were based on our recently published study [38] in which we
evaluated the effect of different electrotransfer parameters on
transgene expression and skin damage using a similar designed
MEA electrode in the guinea pig model. The pulse parameters of
250 V/cm and 150 ms were found to give the highest expression with
minimal damage to the skin. Increasing the field strength did not
result in increased expression. For a single 200 μL injection or four
50 μL adjacent injections, four individual pulse applications were
applied without change of pulse parameters.
2.4. Living imaging of luciferase expression
At different selected time points after delivery, animals were
anesthetized then administrated intradermally with the same DNA
volume of D-luciferinwith 7.5 mg/mL in PBS buffer (Goldbio, St. Louis,
MO, USA). Assessment of photonic emissions using the IVIS Spectrum
system (Caliper Life Sciences, Hopkinton, MA, USA)) was performed
1.5 min after injection of D-luciferin. Background luminescence was
determined by measuring luminescence from area without DNA
injection.
2.5. GFP expression
Each excised sample was immediately frozen on dry ice. After
visualization of GFP expression was observed and obtained by a
fluorescence stereoscope (Leica Model MZFL III, Leica, Heerbrugg,
Switzerland), the specimens were embedded in tissue freeze media
OCT compound (ElectronMicroscopy Sciences, Hatfield, PA) and frozen
at −80 °C freezer. Several frozen sections (8 μm thickness) were cut
from each sample. Each sectionwasfixed in 25% Acetone+75% Ethanol
20 min and then washed twice in PBS. It was dried under dark and
mounted into a coverslip with VECTASHIELD®mounting mediumwith
DAPI (Vector Laboratories, Burlingame, CA). Sectionswere examined by
Olympus BX51 fluorescent microscopy (Olympus, Tokyo, Japan) for the
presence of GFP.
2.6. Histological analysis
Each specimen was embedded, sectioned and fixed as mentioned
above. Sections were dehydrated in 95% ethanol for 30 s, stained in
hematoxylin solution for 5 min, rinsed with tap water for 3 min,
classified in 1% acid alcohol for 10 s, washed with running tap water
for 1 min, blued in 0.2% ammonia solution for 30 s, washed in running
tap water for 3 min, rinsed in 95% alcohol, 10 dips, counterstained in
eosin Y solution for 45 s, dehydrated through 95% alcohol, 2 changes
of absolute alcohol, 10 dips each, cleared in 2 changes of xylene, 10
dips each, mounted with xylene based mounting medium. Sections
were examined by Olympus BX51 microscopy.
2.7. Statistical analysis
All values are reported as the mean±SD. Analysis of luciferase
activity was completed using a 2-tailed Student's t-test when
comparing two groups. Statistical significance was assumed at
pb0.05. All statistical analysis was completed using the SigmaPlot
10.0.
3. Results
3.1. The level and duration of gene expression were significantly
increased by intradermal DNA injection and non-invasive skin EP
The correlation between the level and duration of gene expression
to the size of the treated areawhen delivering by EPwith theMEAwas
evaluated by in vivo bioimaging. As shown in Fig. 1A, the maximum
level of luciferase expression was achieved one day after delivery.
While expression in the non-electroporated sites decreased dramat-
ically by day 2 the expression of EP-treated sites was stable until day
15. The average levels of gene expression in the EP-treated groups
were 2 to 3 logs higher than in the non-EP-treated groups from days 2
to 15. Among the different EP-treated groups, luciferase expression
increased 3.7 to 6.3 fold in 200 μL DNA with one EP application
compared to 50 μL DNA with one EP application from days 1 to 8 after
delivery. However, the skin receiving 200 μL DNA and four EP
applications expressed the highest level of protein with a 4.5 to 15.8
fold increase in expression compared to 50 μL DNA with one EP
application from day 1 to day 12 (Pb0.05 for the most time points).
(Table S1). At day 22 after delivery, the luciferase expression of EP-
treated skin decreased to the level of DNA injection only, both of
which were still slightly increased as compared to background.
Given these findings, we wanted to address whether we could
achieve long-term gene expression by repeated deliveries with MEA
EP delivery. Based on the previously stated results, a one-time
delivery would result in maximum gene expression within 24 h and
would remain relatively constant through day 15. Therefore, we
aimed to attempt three deliveries at the same site and to produce
longer-term expression. The delivery time points were selected to be












day 0, day 15 and day 29. Our results from these experiments
indicated that subsequent deliveries could not increase or even match
gene expression of initial levels nor could it enhance the duration of
the expression beyond the initial delivery time frame (Fig. 1B). While
in all samples both EP and the plasmid injection only control had
similar luciferase expression at one day post second delivery, the
expression rapidly decreased and reached background levels by day
12 after the second delivery (day 27). For the third delivery, both non-
EP and EP-treated sites could not reach high expression. The gene
expression of all sites very rapidly dropped to the background level by
day 4 after the third delivery (Day 33). The studywas performed twice
and reached the same conclusion.
3.2. Gene expression by skin EP delivery with the MEA was exclusively in
the epidermal layer of the skin
Fluorescence stereoscopy and microscopy were used to observe
the distribution of the gene transfected cells in the guinea pig skin
after i.d. DNA injection and EP. Using fluorescence stereoscopy, no
expression was observed in either the non-EP or EP-treated sites at
1 h post-delivery. However, green florescence protein (GFP) expres-
sion of non-EP skin was present at day 1, decreased rapidly to
scattered dots by day 2, and no expression was observed by day 7 or 9
(Fig. 2A, 50 μL-IO). In the EP-treated skin, GFP-expressing areas were
larger than those of non-EP controls and the fluorescence intensity
was maintained at similar levels till day 7 (Fig. 2A, 50 μL-1EP or
200 μL-4EP). At day 9, very few fluorescence-bright dots were
observed in EP-treated skin. No fluorescence was observed in non-
treated controls.
To visualize the localization of gene-expressing cells after non-
invasive surface EP, cross-sections of the skin were labeled with DAPI
and PI for fluorescence microscopy observation. Surprisingly, almost all
GFP-expressing cells from EP-treated skinwere located in the epidermal
layer at day 2 or day 7 (Fig. 2B). Gene-expressing cells at day 2were cells
with nuclei beneath the stratum corneal layer of the epidermis but by
day 7 thoseGFP-expressing cells had lost their nuclei andmoved into the
stratum corneum. For DNA injection alone, no expression was observed
in the epidermal layer of skin at either day 2 or day 7 (Fig. 2C,D). Skin
receiving plasmid injection only expressed the luciferase and GFP
transgenes one day after delivery (Figs. 1 and 2A). GFP-expressing cells
were observed in the dermis for bothDNA injection only andEP delivery
groups after one day (Fig. S1). These transgene-expressing cells were
scattered in the areas surrounding the DNA injection site and
occasionally were seen close to the epidermal layer. However, no
expressionwas found in the epidermis for theDNA injection alonewhile
GFP expression was observed there for the skin treated with EP after
delivery day 1 (Fig. S1).
3.3. Skin damage caused by noninvasive electroporation using MEA was
limited and completely recoverable
For potential clinical applications, any skin damage including
significant infiltration, necrosis and scar formation would limit the
therapeutic applications of the MEA. Under our parameters for EP, no
severe tissue damage, such as skin burning, ulceration or scar
formation, was found from gross observation (Fig. 3A). Skin redness
and prints of the MEA array did occur after EP delivery but were not
present by day 5. Some hair loss was noted in the area of EP
application. However, the hair loss was transient and hair grew back
within one week after the delivery. Damage was also assessed
histologically by hematoxylin and eosin (H&E) staining. In contrast to
DNA injection alone, which did not present with any damage, focal
cell vacuolization or degeneration in the epidermal layer was
observed for all EP-treated skin (Fig. 3B). By day 7, this cell
vacuolization was no longer present. Notably, most epidermal cells
were morphologically normal after EP delivery. The statistically
significant infiltration and necrosis, which were seen in the epidermal
or dermal layer in our previous study with the 4 plate electrode [25],
was not observed in this study.
3.4. Skin EP with the MEA facilitated intradermal DNA diffusion into the
epidermal direction
Although DNA was administered intradermally before EP, the
transfected cells were exclusively indentified within the epidermis,
not the dermis (Fig. 2). To elucidate the association between DNA
distribution and gene expression, Fluorescein or CyTM3-labeled
plasmid was administered either by i.d. injection alone or with EP
using the MEA. The skin samples were harvested and analyzed by
fluorescence stereoscopy 1 h after delivery. While dense DNA-
fluorescence with sharp margins was shown in injection alone
samples (Fig. 4B, 50 μL-IO), larger, dimmer peripheral DNA distribu-
tions were observed in the skin with EP delivery (Fig. 4C, 50 μL-EP).
Under fluorescence microscopy, DNA was distributed symmetrically
from high concentration in the injection site to low concentration at
both peripheral areas in the dermis (Fig. 4D). There was no labeled
DNA which appeared close to the epidermis after DNA i.d. injection
Fig. 1. Kinetic of gene expression in skin after i.d. DNA (gWiz-Luciferase) injection and
non-invasive EP. Delivery groups, 50 μL-IO: 50 μL DNA without EP; 50 μL-1EP: 50 μL
DNA with 1 EP on the injection site; 200 μL-IO: 200 μL DNA without EP; 200 μL-1EP:
200 μL DNA and 1 EP; 200 μL-4EP: 200 μL DNA and 4 EPs; 50 μL×4-IO: 4 injections with
50 μL DNA without EP; 50 μL×4-4EP: 4 injections with 50 μL DNA and each EP on the
injection site. A, Time course of luciferase expression in guinea pig skin after 1 delivery
at d0. Bars represent mean±SD. 4–5 sites were analyzed for each delivery. B, Time
course of luciferase expression in guinea pig skin with 3 deliveries, separately at d0, d15
and d29. Bars represent mean±SD. 5–6 sites were analyzed for each delivery. p/
s=photons/second.












alone (Fig. 4D). However, EP changed this pattern. The relative
scattered and spread distribution was seen from injection site to the
epidermal direction. A few labeled DNA spots were observed in the
epidermis (Fig. 4E).
4. Discussion
While many studies focus on the application of skin EP for
superficial cancers [6,39], a few studies have demonstrated that
significant serum levels of products could be obtained by EP gene
transfer to skin [24,31,34]. Considering the easy access and large area
of the skin, the expression level could be potentially increased by
increasing the area treated to achieve the effective protein concen-
tration in serum. Indeed, luciferase expression could be significantly
enhanced by increasing the delivery area. Here we demonstrated that
local protein expression levels can be increased by an average 7.8 fold
(d1 to d12, pb0.01) by quadrupling the size of the treated area
(200 μL-4EP compared to 50 μL-1EP). It could, however, be inter-
preted as marginal electric field effect because four pulse deliveries
were applied adjacently. The marginal areas were exposed to
repeated electrical field, so more cells could have been transfected
and/or more DNA transferred into the same cells. To achieve more
protein product locally or systemically, we can simply apply multiple
injections and pulse deliveries or expand theMEAwithout any change
of EP parameters, for example the current 4×4 array electrodes could
be expanded to a 7×7 array to assure a 4-fold increase of size.
One of the critical aspects for skin EP is the duration of expression
after electrogene transfer. The kinetics of luciferase expression inmice
has been studied by several groups [24–26,40–42]. A significant
increase in gene expression was obtained by skin EP with plate
electrodes in two weeks [24–26,40]. Different expression patterns
were reported, which may be due to different electrodes and/or
parameters of EP chosen by the different groups. EP with needle
electrodes showed increased expression for longer than 3 weeks
[41,42], most likely because needles can achieve deeper penetration of
electrical field or may facilitate DNA diffusion from the injection site
into the adjacent dermis or even muscle layers [42,43]. Interestingly,
in guinea pig, luciferase expression in the epidermis reached the first
peak at day 1, then slightly dropped at day 2 and slowly reached the
second peak at day 8. The significant expression after EP can last up to
15 days. If EP delivery method targets to the epidermal layer of the
skin as in this study, the duration of transgenic expression very likely
depends on the epidermal turn over.
Multiple EP treatment applications were often utilized to treat
cancer in animal models or clinical trials [25,32,34,35]. In this study,
multiple deliveries were designed to achieve long-term expression
and assess the feasibility of skin EP for protein replacement.
Unfortunately, luciferase expression patterns after the second and
third deliveries were shown to be completely different as compared to
the first delivery. No definite interval of high expressionwas observed
after the second and third deliveries. The presence of anti-luciferase
IgG antibodies was discovered in the guinea pig serum after three EP
deliveries and is most likely the cause of the change in expression
patterns (Fig. S1). Vandermeulen et al. also demonstrated that high
titers of anti-luciferase IgG antibody were induced by multiple intra-
pinna electroporations (one priming and two boosts) in mice [44].
These results indicate that since luciferase is an exogenous protein
capable of eliciting an immune response, it is not a good reporter for
multiple deliveries or long-term expression studies in guinea pigs. On
the other hand, the capability to induce an immune reaction to a weak
antigen by skin EP is helpful for researchers to design an effective
vaccination against infectious diseases or cancer [10,44–51].
The distribution of transfected cells by EP is dependent on both the
skin differences between the animals as well as the electrodes
employed. Our results show that uniform epidermal expression in
guinea pig skin can be obtained by EP with the MEA. The study of
Fig. 2. Distribution of gene-expressing cells after i.d. DNA (gWiz-GFP) injection and non-
invasive EP. Skin samples were collected post-delivery, 1 h, day 1, day 2, day 7 or day 9.
Samples were analyzed by immunofluorescencemicroscopy. Delivery group, 50 μL-IO: 50 μL
DNA without EP; 50 μL-1EP: 50 μL DNA with 1 EP on the injection site; 50 μL×4-4EP: 4
injection of 50 μL DNA and each EP on the injection site; 200 μL-1EP: 200 μL DNA and 1 EP;
200 μL-4EP: 200 μL DNA and 4 EPs. A, One representative picture of 3 treated sites. (B, C, D)
Total 6 cryosections (2 sections per sample) of each delivery were analyzed. Cell nuclei were
blue-stained by DAPI. GFP-expressing cells were shown in green. (C, D) Cell nuclei and
stratum corneumwas shown red-stained by propidium iodide. B, One representative section
of each delivery was presented for post-delivery day 2 and day 7 (magnification=100, scale
bar=100 μm).C,One representative section frompost-deliveryday2(magnification=200).D,
One representative section frompost-delivery day7(magnification=200, scale bar=100 μm).












intradermal DNA EP with the caliper electrode demonstrated that the
transfected cells were present at the dermis in mouse while at the
epidermis in xenograft human skin [40,44]. Moreover, EP with tweezer
electrodes resulted in transgenic expression in the lower dermal region
of rabbit skin [52]. However, EP with needle array electrodes could
result in transfected cells in the dermis, epidermis, hypodermis even
around the muscle layer, but mainly in the panniculus carnosus muscle
layer of the mice [42,43] or dermis of the pig [53]. For plate electrodes,
the electrical field went through all layers of skin between the two
plates [54]. For the needle electrodes, the electrical field was confined
between the two (array) needles in the skin [54]. However, the electric
field generated by the MEA is designed to decrease the depth of
penetration thereby reducing muscle contraction. We observed signif-
icantly reduced muscle twitching when using the MEA as compared to
the 4 plate electrodes or needle electrodes.
It is necessary to point out that non-invasive electrodes such as
plates and the MEA do not directly affect DNA distribution after i.d.
administration. On the other hand, the needle electrodes may
penetrate the injection site and facilitate DNA diffusion into the
surrounding area. This is a potential explanation for the spread of
expression usually observed by EP with needle arrays [42,53]. The
histological characterization of skin also plays a role in the
distribution of transgenic expression. With the same plate electrodes
or i.d. DNA injection only, both Zhang's and Hengge's groups
demonstrated that gene-expressing cells in the dermis for mouse
skin but in the epidermis for xenografted human skin [40,55]. The
epidermal expression in guinea pig by theMEAmay also be associated
with its similarity to human skin structure [36,37].
Consistent with our previous report [27], EP with the MEA could
greatly reduce the adverse effects of needle or plate electrodes while
comparable or higher expression levels were achieved. Minimal skin
damage was observed grossly as well as histologically and complete
recovery after EP was observed. Tissue damage such as the dermal
necrosis or burning seen in previous studies done by our group [25] and
others [56] was not observed in this study. When multiple deliveries
with theMEA were applied to the same sites, skin redness and hair loss
were slightly increased for both DNA injection alone and EP, but
completely healed by day 5 (Fig. S2). These resultswere consistentwith
our previous finding in mice where skin damage was increased by
repeated gene delivery with plate electrodes [26]. Both studies suggest
that repeatedapplicationofEPpulses at the same site shouldbeavoided.
Based on the DNA distribution and gene expression we can see
there are two types of expression for non-invasive EP skin delivery
with the MEA in guinea pigs. One is local expression around DNA
injection site with the duration of 1–2 days. Another is epidermal
expression distant from DNA injection site with the duration of
15 days. The first pattern is obviously independent of EP because it
occurred in both DNA injection alone and EP-treated locations
(Figs. 1A,B and 2A). The latter pattern is specifically related to MEA
EP because it did not occur with DNA injection alone. The two patterns
of transgenic expression may explain why the luciferase expression
with EP dropped slightly at day 2. It is possible that day 1 expression
with EP included the component related to non-EP dependent
expression and that waned rapidly. Further histological analysis of
DNA distribution (Fig. 4D,E) and gene expression location (Figs. 2B
and S3) demonstrated that MEA EP first facilitates DNA diffusion from
Fig. 3. Gross observation and histology of skin after i.d. DNA injection and non-invasive
EP. A, Skin observation after delivery. Pictures were taken at post-delivery day 1, day 2
and day 5. One representative picture of 4 to 5 sites was shown here. Delivery group,
50 μL-IO: 50 μL DNA without EP; 50 μL-1EP: 50 μL DNA with 1 EP on the injection site;
200 μL-IO: 200 μL DNA without EP; 200 μL-1EP: 200 μL DNA and 1 EP; 200 μL-4EP:
200 μL DNA and 4 EPs; 50 μL×4-IO: 4 injections with 50 μL DNA without EP; 50 μL×4-
4EP: 4 injections with 50 μL DNA and each EP on the injection site. B, Hematoxylin and
eosin-stained skin samples. One representative of 3 treated sites was presented here for
post-delivery day 2 or day 7. Arrows indicate the focal cell vacuolization. (magnifica-
tion=200, scale bar=100 μm).












the dermal layer into the epidermal layer and then electrotransfer of
DNA into epidermal cells.
5. Conclusion
Efficient gene delivery can be obtained by skin electroporation
with a non-invasive multielectrode array. The high expression can be
maintained for up to 15 days after single skin EP with MEA. The gene
expression level can be easily multiplied by increasing the delivery
area without any change of EP parameters. Skin EP with MEA was
found to target the epidermal cells for gene transfer. In contrast to
plate electrodes, skin EP with MEA significantly reduced muscle
twitching and resulted in minimal and completely recoverable skin
damage. However, multiple EPs with MEA are not recommended to
apply in the same site because of the potential of skin damage. Further
studies will focus on whether we can translate these findings into
vaccination, cancer immunogene therapy or long-term endogenous
gene expression for protein deficiencies.
Supplementarymaterials related to this article can be found online
at doi:10.1016/j.jconrel.2011.01.014.
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